

Regulatory clarity to unlock re-rating

Investment Overview

Positioning for regulatory overhang lift. The ongoing antitrust investigation has sparked concerns over its potential impact on earnings. Trip's share price has underperformed the sector (Trip -30% vs. HSTECH -12% YTD). The current valuation of 12.8x FY26E PE, at its lowest level since reopening in 2023 (vs. trading range of 13-39x post reopening), suggests potential earnings impact has been reflected. Drawing from precedents, the investigation is expected to conclude in early May. Trip's stock now offers a compelling accumulation opportunity ahead of a potential rerating once the regulatory overhang lifts.

Regulatory impact largely reflected; rerating path ahead. Market concerns that antitrust scrutiny could require Trip to dismantle its Special (exclusive) and Gold (price-favorable) hotel brands would primarily affect the company's domestic hotel segment, which we estimate accounts for ~28% of FY26F revenue. That said, the earnings impact is expected to be manageable. Our sensitivity analysis shows that every 10% decline in domestic hotel GMV reduces group earnings by ~5%, and every 1ppt drop in take rate cuts earnings by ~6%. Our scenario analysis indicates the market has largely factored in the potential regulatory impact under our base case by assuming increased competition and a certain degree of commission rate compression. Removal of the overhang offers a clear path to rerating (P/E multiple returning to 16x) with 22% upside. We also see a likelihood of our bull case scenario, where the outcome is limited to a one-off financial penalty in line with precedents, delivering a compelling 38% upside driven by both valuation recovery and upward earnings revisions.

BUY with unchanged TPs of HKD563/USD72. We remain positive on Trip's medium- to long-term growth prospects, underpinned by secular growth in Chinese travel demand and international platform. Meanwhile, recent signs that ChatGPT is pulling back from direct travel checkouts should ease concerns around take-rate dilution on OTA platforms. Our TP is pegged to 18x non-GAAP PE multiple based on 12-month forward earnings, representing 1SD below the 3-year average to reflect moderation in domestic travel and ongoing regulatory uncertainty.

Risks

(1) Irrational market competition leads to higher subsidies; (2) Government regulatory risks.

Forecasts and Valuation

FY Mar (CNYmn)	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
Revenue	44,562	53,377	62,510	69,620	78,659
EBITDA	13,213	17,856	16,971	19,361	22,262
Pre-tax Profit	11,752	19,831	39,201	20,201	23,102
Net Profit	9,918	17,067	33,294	17,169	19,635
Net Pft (Pre Ex.)	13,071	18,041	31,839	19,869	22,635
Net Pft Gth (Pre-ex) (%)	910.1	38.0	76.5	(37.6)	13.9
EPS (HKD)	16.7	27.8	56.3	29.7	34.0
EPS Pre Ex. (HKD)	22.0	29.4	53.9	34.4	39.2
EPS Gth Pre Ex (%)	903.2	33.3	83.5	(36.1)	13.9
Diluted EPS (HKD)	16.3	26.4	53.0	28.0	32.0
Net DPS (HKD)	0.00	0.00	0.00	0.00	0.00
BV Per Share (HKD)	200.3	219.1	272.2	311.4	349.1
PE (x)	23.9	13.9	7.2	12.8	12.2
PE Pre Ex. (x)	18.2	13.2	7.5	12.0	10.6
P/Cash Flow (x)	19.4	19.4	nm	23.9	24.4
EV/EBITDA (x)	16.8	11.1	11.4	9.5	7.8
Dividend Yield (%)	nm	nm	nm	nm	nm
P/Book Value (x)	2.0	1.8	1.5	1.3	1.2
Net Debt/Equity (x)	cash	cash	cash	cash	cash
ROAE (%)	8.5	12.9	21.3	9.5	9.7

Source: DBS, DBS HK

BUY

Last Traded Price: HKD410.40

Price Target 12-mth: HKD563.00

BUY

Last Traded Price: USD54.12

Price Target 12-mth: USD72.00

Analyst

Ben WONG | benwongkf@dbs.com

Andy YU | andyyuakh@dbs.com

Edmond FOK | edmondfok@dbs.com

Sachin MITTAL | sachinmittal@dbs.com

What's New

- Investigation expected to conclude in early May, based on precedents
- Potential impact from antitrust mainly on domestic hotel segment (~28% of FY26F revenue); however, the earnings impact appears manageable
- Uncertainty reflected with PE at its lowest level since reopening; removal of the overhang could drive 22% upside in our base case, or 38% in our bull case (one-off fine)
- Best proxy for robust Chinese travel demand and overseas expansion; agentic AI impact limited given Trip's strong moat; Maintain BUY, TPs unchanged at HKD 563 / USD 72

Key Financial Data (FY Dec)

Bloomberg Ticker	9961 HK / TCOM US
Sector	Consumer Services
Market Cap (USDbn)	44.6
3m Avg. Daily Val (USDmn)	196.8
Major Shareholders	(%)
Baidu Holdings Ltd	9.4
Blackrock Inc	5.0
Free Float (%)	90.6

Closing Price as of 15/04/2026

Source: Twelve Data, DBS, Visible Alpha

Trip.com Group Ltd Share Price



Financial Summary

FY Dec (CNYmn)	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
Sales	44,562	53,377	62,510	69,620	78,659
% y/y	122.2	19.8	17.1	11.4	13.0
Gross Profit	36,389	43,304	50,287	56,114	63,478
% y/y	134.4	19.0	16.1	11.6	13.1
EBITDA	13,213	17,856	16,971	19,361	22,262
% y/y	3,404.8	35.1	(5.0)	14.1	15.0
Net Profit (Loss)	9,918	17,067	33,294	17,169	19,635
% y/y	606.9	72.1	95.1	(48.4)	14.4
FCF	12,245	12,258	(7,116)	10,017	9,802
% y/y	nm	0.1	nm	nm	(2.1)
CAPEX	(9,759)	(7,367)	(9,600)	(9,600)	(9,600)
% y/y	(23.5)	(24.5)	30.3	0.00	0.00
EBITDA Margin (%)	29.7	33.5	27.1	27.8	28.3
Net Margin (%)	22.3	32.0	53.3	24.7	25.0
ROA (%)	4.8	7.4	13.1	6.2	6.5
ROE (%)	8.5	12.9	21.3	9.5	9.7
Tax Rate (%)	14.9	13.1	14.8	14.6	14.6

Source: DBS, DBS HK

Revenue and Profit Trend FY



Source: DBS, DBS HK

Valuation Metrics

FY Dec	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
PE (x)	23.9	13.9	7.2	13.9	12.2
P/B (x)	2.0	1.8	1.5	1.3	1.2
Dividend Yield (%)	nm	nm	nm	nm	nm
EV/EBITDA (x)	16.8	11.1	11.4	9.5	7.8
FCF Yield (%)	5.5	6.2	nm	5.5	5.7
Net DPS (HKD)	0.00	0.00	0.00	0.00	0.00
BV Per Share (HKD)	200.3	219.1	272.2	311.4	349.1

Source: DBS, DBS HK

Credit & Cashflow Metrics

FY Dec	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
Debt / Equity (x)	0.4	0.3	0.2	0.2	0.2
Net Debt / Equity (x)	cash	cash	cash	cash	cash
Debt / Assets (x)	0.2	0.2	0.1	0.1	0.1
EBITDA / Int Exp (x)	nm	nm	nm	nm	nm
Debt / EBITDA (x)	3.4	2.2	1.8	1.7	1.6
Receivables Days	112.7	122.0	138.5	150.6	146.6
Days Payable	1,326.4	1,379.8	1,238.2	1,155.0	1,021.7
Inventory Days	nm	nm	nm	nm	nm

Source: DBS, DBS HK

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document


What's New

Regulatory clarity to unlock re-rating

- Investigation expected to conclude in early May, based on precedents
- Potential impact from antitrust mainly on domestic hotel segment (~28% of FY26F revenue); however, the earnings impact appears manageable
- Uncertainty reflected with PE at its lowest level since reopening; removal of the overhang could drive 22% upside in our base case, or 38% in our bull case (one-off fine)
- Best proxy for robust Chinese travel demand and overseas expansion; agentic AI impact limited given Trip's strong moat; Maintain BUY, TPs unchanged at HKD 563 / USD 72

Recent antitrust developments raised concerns over intensifying competition in the domestic hotel segment. A common question we receive is whether potential antitrust penalties will require Trip to fully dismantle its Special (特牌) and Gold (金牌) hotel brands. These two categories of hotels pay higher take rates (10-15% gross) in exchange for superior traffic support from Trip. These exclusive brands have long served as Trip's core supply-side moat. Special hotels are restricted to listing exclusively on Trip and barred from competing platforms. Their removal will directly erode Trip's unique inventory advantage and weaken its ability to control supply and pricing. The Gold brand, meanwhile, primarily allows hotels to offer Trip more favorable prices, meaning that room rates on other OTA platforms are not lower than those on Trip, thereby preserving its competitiveness. The removal of exclusive hotel listings and pricing advantages would directly benefit rivals such as Meituan and Fliggy (subsidiary of Alibaba), which have long been constrained by limited access to high-end hotel supply and weaker pricing leverage. Accordingly, Trip's share price has fallen around 30% over the past three months following the company's announcement that China's State Administration for Market Regulation (SAMR) has launched an investigation into the company under the Anti-Monopoly Law. Valuation has derated from ~20.0x to currently 12.8x, at its lowest P/E multiple since reopening in 2023 (vs. trading range of 13–39x post reopening).

1-yr forward PE of Trip and Tongcheng



Source: Bloomberg, DBS HK

A snapshot of potential impact from anti-trust regulations and key implications for Trip

Event	Direct impact on Trip	Implications to Trip
Potential loss of exclusive access to Special hotels and weakening of competitive pricing for Gold hotels	Domestic hotel GMV growth	1) Potential loss of unique inventory advantage; rivals gain access to previously Trip-exclusive high-end Special hotel supply. This makes up 30–40% of Trip's domestic hotel GMV
	Domestic hotel take rate	2) Competitors can offer equal or better prices for Gold hotels vs. Trip, weakening Trip's pricing power and potentially reducing take rate
	Outbound hotel and Int'l platform	No impact as most complaints come from domestic hoteliers
Air & railway booking (processing fee model)	Transportation GMV growth and take rate	Given that China's airline and railway industries are dominated by state-owned enterprises and OTAs are limited to collecting only processing fees for bookings, this segment is unlikely to face similar antitrust scrutiny


Source: DBS HK

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

How impactful would it be on Trip’s earnings profile?

- 1. Given that China's airline and railway industries are dominated by a handful of state-owned enterprises, and OTAs are restricted to collecting only processing fees for facilitating bookings, we believe the dynamics of this segment limit the ability of any single company to gain an advantage through unfair practices.
- 2. We believe outbound and international platforms are not the key regulatory focus, as most complaints come from domestic hoteliers. As such, we expect growth momentum for the two segments to remain intact.
- 3. In our view, the domestic hospitality segment is more likely to draw scrutiny from SAMR. As illustrated in the chart below, Trip is expected to generate ~28% of its FY2026F revenue from domestic hotel bookings.

Trip FY26F revenue breakdown (%)




Source: Companies, DBS HK

Potential impact on domestic hotel segment:

1) **Potential loss in hotel booking volume?** Trip does not disclose the exact contribution of Special label hotels to total hotel GMV. Using industry data as a reference, where 5-star hotels contribute ~37% of total industry GMV, we estimate that Special label hotels account for 30–40% of Trip’s hotel GMV. The removal would allow competitors such as Meituan and Fliggy to access premium hotel inventory and enhance their pricing competitiveness, thereby strengthening their hotel supply. However, we expect any resulting loss of market share to be manageable. Trip’s position as the most comprehensive one-stop travel platform, spanning transportation (i.e. railways and domestics/overseas airlines), tourist attractions to hospitality, combined with its premium service capabilities and loyal high-value customer base, should continue to serve as key defensive moats against market share erosion.

Total revenue breakdown by hotel star in China



Source: Ministry of Culture and Tourism, data as of 2024

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document


Special and Gold labeled hotels on Trip APP (before vs now)



Source: Trip APP

Remark: Trip has removed the Special and Gold labels from its app

Search results on Meituan and Tongcheng APPs




Source: Meituan and Tongcheng APPs

Remark: We are unable to find the same hotels on Meituan APP but available on Tongcheng

2) Likely compression in take rate as competition heats up? If competitors gain access to previously exclusive inventory, Trip may face pressure to lower take rates to remain competitive. Nevertheless, we believe the impact will be moderate. The company can continue to deepen hotel partnerships through advertising and traffic support. Moreover, the loyalty of its high-end users should help mitigate downward pressure on pricing power and limit potential market share erosion. In our recent conference call with Atour, when asked whether the antitrust investigation into Trip would help reduce commission rates for hotel merchants, management indicated that it is unlikely to materially impact OTA commission rates, noting there are ways for Trip to offset the impact through alternative fees (see [link](#) for takeaways). While Douyin and JD have previously attempted to compete by undercutting take rates, such as JD's zero take rate offer last year, the impact on Trip's domestic hotel take rate has remained limited.

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

Trip's domestic hotel take rate trend

Source: Visiblealpha, DBS HK

We performed sensitivity analyses to assess the impact on Trip's earnings:

Earnings sensitivity to domestic hotel GMV and take rate. By way of sensitivity, we estimate that every 10% decline in domestic hotel GMV would reduce the group's FY26F earnings by 5%, and every 1ppt change in the hotel take rate would drive a 6% earnings impact, all else equal. In an extreme case where domestic hotel GMV and take rate are both impacted meaningfully, we estimate that ~17-26% of Trip's earnings would likely be impacted on top of our existing forecasts.

Earnings sensitivity to changes in domestic hotel GMV and take rate

Domestic hotel take rate	Domestic hotel GMV growth							
	15.0%	10.0%	5.0%	0.0%	-5.0%	-10.0%	-15.0%	-20.0%
8.2%	4%	2%	0%	-3%	-5%	-8%	-10%	-13%
7.9%	2%	1%	0%	-5%	-7%	-10%	-12%	-14%
7.5%	0%	-3%	-5%	-7%	-9%	-12%	-14%	-16%
7.0%	-4%	-6%	-8%	-10%	-12%	-14%	-17%	-19%
6.5%	-7%	-9%	-11%	-13%	-15%	-17%	-19%	-21%
6.0%	-11%	-13%	-14%	-16%	-18%	-20%	-22%	-24%
5.5%	-14%	-16%	-18%	-19%	-21%	-23%	-24%	-26%

Source: DBS HK

Remark: Our current forecast is highlighted in orange. This table shows the incremental impact on Trip's earnings under different assumptions

Valuation (PE) sensitivity under different domestic hotel GMV growth and take rate assumptions

Domestic hotel take rate	Domestic hotel GMV growth							
	15.0%	10.0%	5.0%	0.0%	-5.0%	-10.0%	-15.0%	-20.0%
8.2%	12.2X	12.5X	12.8X	13.2X	13.5X	13.9X	14.3X	14.7X
7.9%	12.5X	12.5X	12.8X	13.4X	13.8X	14.1X	14.5X	14.9X
7.5%	12.8X	13.1X	13.5X	13.8X	14.1X	14.5X	14.9X	15.3X
7.0%	13.3X	13.6X	13.9X	14.2X	14.6X	15.0X	15.3X	15.7X
6.5%	13.8X	14.1X	14.4X	14.7X	15.1X	15.4X	15.8X	16.2X
6.0%	14.3X	14.6X	15.0X	15.3X	15.6X	16.0X	16.3X	16.7X
5.5%	14.9X	15.2X	15.5X	15.8X	16.2X	16.5X	16.9X	17.3X

Source: DBS HK

Remark: Our current forecast is highlighted in orange. This table shows Trip's implied PE multiple under different assumptions

What's already priced in now? The table below quantifies the earnings impact under different GMV growth and take-rate assumptions for Trip's domestic hotel division and outlines the key scenarios relevant to Trip. Under our base case, Trip's shares trade at 12.8x FY26E P/E, at its lowest P/E multiple since reopening in 2023 (vs. trading range of 13-39x post reopening). The stock has corrected around 30% since the investigation was announced, which appears to have already reflected the potential earnings impact from 1) increased competition, and 2) concerns around commission rate compression. A rerating to 16x P/E (implying 22% upside) under our base case is well within reach once the regulatory overhang is removed, slightly below the FY25 average, a time when the market was expecting moderation in domestic travel while overseas growth remained robust.

We do not rule out a bull case scenario materialising, where the outcome is limited to a one-off financial penalty in line with precedents, which would deliver a compelling 38% upside. Valuation should rerate towards a more reasonable level of ~18x forward P/E with 2-4% upward earnings revisions. Trip's stock therefore offers an attractive accumulation opportunity ahead of a potential rerating once the regulatory overhang lifts.

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

Trip scenario analysis points to favourable risk-reward

Scenario	Regulatory Outcome	Key Operational Impact	Earnings Impact	Potential valuation rerating (Forward P/E)	Remark
Bull Case	1) One-off fine (1-10% of sales) 2) Special/Gold programs intact	1) No loss of exclusivity 2) Take rates stable at FY25's levels 3) Limited share loss to Meituan/Fliggy/Tongcheng	~2-4% upside	Returns to FY25 historical avg: ~18x <i>(implying 38% upside)</i>	A time when the market was expecting moderation in domestic travel, but overseas growth remained robust
Base Case	1) Unwind "Special" exclusivity 2) "Gold" price parity modified	1) Slower domestic hotel GMV growth: ~-5% 2) Take rate compression: ~30-50bps lower than FY25	Current consensus level	Returns to ~16x <i>(implying 22% upside)</i>	Valuation discount relative to the FY25 average level to reflect slower GMV and a lower take rate
Bear Case	1) Special/Gold programs fully 2) Forced commission rate caps	1) Domestic hotel GMV declines: 10-20% 2) Take rate compression: ~2-3 ppts 3) Meaningful high-end hotel inventory loss	~17-26% downside	n.m.	n.m.

Source: DBS HK

Recap of anti-trust precedents

Companies	Alibaba	Meituan
Investigation initiated	24-Dec-20	26-Apr-21
Fine issued	10-Apr-21	8-Oct-21
Investigation duration	~3.5 months (107 days)	~5.5 months (189 days)
Fine amount	Rmb18.228bn; % of annual revenue: ~3.6%; % of annual net profit: ~12.2%	Rmb3.442bn; of annual revenue: ~3.0%; % of annual net profit: ~73.1%
Stock price performance during the investigation period	-12.30%	-16.3%
Stock price performance following the close of the investigation (with 1-mth)	+8%	+17%

Source: Companies, 36Kr, DBS

Agentic AI unlikely to reshuffle OTA landscape. We believe concerns around AI disruption are overdone, as Trip.com's supply strength, merchant relationships and fulfillment capabilities remain intact. Meanwhile, recent signs that ChatGPT is pulling back from direct travel checkouts should help ease lingering concerns around take-rate dilution on OTA platforms. Our conversations with OTA management also suggest that the launch of hotel booking features in AI assistant apps like Qwen is making slow progress. The impact on OTAs remains uncertain. Overall, we continue to see a solid structural outlook, supported by resilient Chinese travel demand and strong overseas platform momentum.

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

Company profile

Founded in 1999 and listed on NASDAQ in 2003 and the HKEX in 2021, Trip.com (formerly named "Ctrip") is the largest online travel platform in China. Trip.com's major revenue comes from (1) accommodation reservations, (2) transportation ticketing, (3) packaged tours, (4) corporate travel, and (5) others, accounting for 40%, 38%, 8%, 5%, and 9% of revenue, respectively, as of FY24.

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

Key Assumptions

FY Dec	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
Domestic hotel average daily rate (Rmb)	352.0	341.0	337.6	341.0	344.4
Domestic hotel room night sold (m)	545.7	600.0	660.0	726.0	798.6
Air ticket revenue (Rmb m)	10,513	10,952	11,777	12,220	12,220

Source: DBS, DBS HK

Segmental Breakdown (CNY, mn)

FY Dec	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
Accommodation reservation	17,257	21,612	26,100	27,351	30,601
Transportation ticketing	18,443	20,301	22,489	26,069	29,529
Packaged tours	3,140	4,336	4,688	5,532	6,417
Others	3,468	4,626	6,404	7,557	8,690
Corporate travel	2,254	2,502	2,829	3,112	3,423
Total Revenue	44,562	53,377	62,510	69,620	78,659

Source: DBS, DBS HK

Income Statement (CNY, mn)

FY Dec	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
Revenue	44,562	53,377	62,510	69,620	78,659
Cost of Goods Sold	(8,173)	(10,073)	(12,223)	(13,506)	(15,181)
Gross Profit	36,389	43,304	50,287	56,114	63,478
Other Opng (Exp)/Inc	(25,065)	(29,127)	(34,514)	(38,013)	(42,476)
Operating Profit	11,324	14,177	15,773	18,101	21,002
Other Non Opg (Exp)/Inc	2,486	3,194	19,866	3,600	3,900
Associates & JV Inc	1,072	2,828	353.0	600.0	600.0
Net Interest (Exp)/Inc	23.0	606.0	1,754	600.0	600.0
Exceptional Gain/(Loss)	(3,153)	(974.0)	1,455	(2,700)	(3,000)
Pre-tax Profit	11,752	19,831	39,201	20,201	23,102
Tax	(1,750)	(2,604)	(5,815)	(2,940)	(3,375)
Minority Interest	(84.0)	(160.0)	(92.0)	(92.0)	(92.0)
Preference Dividend	0.00	0.00	0.00	0.00	0.00
Net Profit	9,918	17,067	33,294	17,169	19,635
Net Profit before Except.	13,071	18,041	31,839	19,869	22,635
EBITDA	13,213	17,856	16,971	19,361	22,262
Revenue Gth (%)	122.2	19.8	17.1	11.4	13.0
EBITDA Gth (%)	3,404.8	35.1	(5.0)	14.1	15.0
Opg Profit Gth (%)	12,768.2	25.2	11.3	14.8	16.0
Net Profit Gth (Pre-ex) (%)	910.1	38.0	76.5	(37.6)	13.9
Net Prop Inc Margins (%)	81.7	81.1	80.4	80.6	80.7
Opg Profit Margin (%)	25.4	26.6	25.2	26.0	26.7
Net Profit Margin (%)	22.3	32.0	53.3	24.7	25.0
ROAE (%)	8.5	12.9	21.3	9.5	9.7
ROA (%)	4.8	7.4	13.1	6.2	6.5
ROCE (%)	5.7	6.8	6.8	7.0	7.4
Div Payout Ratio (%)	0.00	0.00	0.00	0.00	0.00
Net Interest Cover (x)	nm	nm	nm	nm	nm

Source: DBS, DBS HK

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

Balance Sheet (CNY, mn)

FY Dec	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
Net Fixed Assets	54,484	52,247	66,820	75,760	84,700
Invt in Associates & JVs	0.00	0.00	0.00	0.00	0.00
Other LT Assets	75,921	78,214	79,517	76,562	76,362
Cash & ST Invt	61,731	79,568	78,458	90,408	102,337
Inventory	0.00	0.00	0.00	0.00	0.00
Debtors	15,591	20,093	27,351	30,086	33,095
Other Current Assets	11,410	12,459	15,241	16,765	18,442
Total Assets	219,137	242,581	267,387	289,582	314,935
ST Debt	25,857	19,433	19,335	21,268	23,395
Creditor	33,174	36,548	40,649	40,649	40,649
Other Current Liab	13,380	18,029	18,185	18,185	18,185
LT Debt	19,099	20,134	11,430	11,430	11,430
Other LT Liabilities	4,621	5,698	5,319	5,319	5,319
Shareholder's Equity	122,184	141,807	170,818	190,987	214,122
Minority Interests	822.0	932.0	1,651	1,743	1,835
Total Cap. & Liab.	219,137	242,581	267,387	289,582	314,935
Non-Cash Wkg. Capital	(19,553)	(22,025)	(16,242)	(11,983)	(7,298)
Net Cash/(Debt)	16,775	40,001	47,693	57,710	67,511
Debtors Turn (avg days)	112.7	122.0	138.5	150.6	146.6
Creditors Turn (avg days)	1,326.4	1,379.8	1,238.2	1,155.0	1,021.7
Inventory Turn (avg days)	nm	nm	nm	nm	nm
Asset Turnover (x)	0.2	0.2	0.2	0.2	0.3
Current Ratio (x)	1.2	1.5	1.5	1.7	1.9
Quick Ratio (x)	1.1	1.3	1.4	1.5	1.6
Net Debt/Equity (x)	cash	cash	cash	cash	cash
Capex to Debt (%)	21.7	18.6	31.2	29.4	27.6

Source: DBS, DBS HK

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document


Cash Flow Statement (CNY, mn)

FY Dec	FY2023(A)	FY2024(A)	FY2025(A)	FY2026(F)	FY2027(F)
Pre-Tax Profit	896.2	934.7	1,053	1,053	1,053
Dep. & Amort.	1,052	1,216	(27,535)	860.0	860.0
Tax Paid	(761.0)	(505.0)	0.00	0.00	0.00
Assoc. & JV Inc/(loss)	0.00	0.00	0.00	0.00	0.00
Chg in Wkg.Cap.	9,256	3,321	(5,284)	(1,504)	(4,685)
Other Operating CF	11,561	14,658	34,250	19,208	22,174
Net Operating CF	22,004	19,625	2,484	19,617	19,402
Capital Exp.(net)	(9,759)	(7,367)	(9,600)	(9,600)	(9,600)
Other Invt.(net)	12,774	11,014	0.00	0.00	0.00
Invt in Assoc. & JV	0.00	0.00	0.00	0.00	0.00
Div from Assoc & JV	0.00	0.00	0.00	0.00	0.00
Other Investing CF	2,904	(9,699)	0.00	0.00	0.00
Net Investing CF	5,919	(6,052)	(9,600)	(9,600)	(9,600)
Div Paid	0.00	0.00	0.00	0.00	0.00
Chg in Gross Debt	(1,961)	(18,091)	2,474	1,934	2,127
Capital Issues	0.00	0.00	0.00	0.00	0.00
Other Financing CF	(466.0)	11,628	0.00	0.00	0.00
Net Financing CF	(2,427)	(6,463)	2,474	1,934	2,127
Currency Adjustments	0.00	0.00	0.00	0.00	0.00
Chg in Cash	25,496	7,110	(4,642)	11,950	11,928
Opg CFPS (HKD)	21.5	26.5	13.1	36.6	41.7
Free CFPS (HKD)	20.6	19.9	(12.0)	17.3	17.0

Source: DBS, DBS HK


Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

Target Price & Ratings History - Trip.com Group Ltd (9961_HK_Equity)



S.No.	Date	Closing Price	12-m Target price	Rating
1	20-May-25	HKD517.00	HKD646.00	BUY
2	19-Nov-25	HKD564.50	HKD684.00	BUY
3	26-Feb-26	HKD413.80	HKD684.00	BUY
4	26-Feb-26	HKD413.80	HKD563.00	BUY

Target Price & Ratings History - Trip.com Group Ltd (TCOM_US_Equity)



S.No.	Date	Closing Price	12-m Target price	Rating
1	20-May-25	USD67.10	USD83.00	BUY
2	19-Nov-25	USD70.89	USD88.00	BUY
3	26-Feb-26	USD53.77	USD88.00	BUY
4	26-Feb-26	USD53.77	USD72.00	BUY

Source: DBS, DBS HK
Analyst: Ben Wong
Andy Yu
Edmond Fok
Sachin MITTAL

RECOMMENDATION DEFINITION

DBS Group Research recommendations are based on an Absolute Total Return* Rating system, defined as follows:
STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)
BUY (>15% total return over the next 12 months for small caps, >10% for large caps)
HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)
FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)
SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Sources for all charts and tables are DBS, DBS HK unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank Ltd, DBS Bank (Hong Kong) Limited ("DBS HK"). This report is solely intended for the clients of DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd, DBS Bank (Hong Kong) Limited ("DBS HK").

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), DBSVUSA, or their subsidiaries and/or other affiliates have a proprietary position in Trip.com Group Ltd recommended in this report as of 31 Mar 2026.

Compensation for investment banking services:

2. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.


Disclosure of previous investment recommendation produced:

3. DBS Bank Ltd, DBS HK, DBSVS, DBSVUSA, their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed on page 1 of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	<p>This report is being distributed in Australia by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946.</p> <p>DBS Bank Ltd, DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws.</p> <p>Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.</p>
Hong Kong	<p>This report has been prepared by a personnel of DBS Bank Ltd, who is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities in Hong Kong pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited ("DBS HK"), a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore.</p> <p>This report is being distributed in Hong Kong by DBS Bank Ltd, DBS Bank (Hong Kong) Limited and DBS Vickers (Hong Kong) Limited, all of which are registered with or licensed by the Hong Kong Securities and Futures Commission to carry out the regulated activity of advising on securities. DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore.</p> <p>For any query regarding the materials herein, please contact Dennis Lam (Reg No. AH8290) at dbsvkh@dbs.com</p>
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	<p>This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies.</p>
	
	Wong Ming Tek, Executive Director, ADBSR
Singapore	<p>This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6878 8888 for matters arising from, or in connection with the report.</p>
Thailand	<p>This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.</p> <p>For any query regarding the materials herein, please contact Chanpen Sirithanarattanukul at DBSVTresearch@dbs.com</p>

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

United Kingdom	<p>This report is produced by DBS Bank Ltd, DBS HK which is regulated by the Monetary Authority of Singapore, Hong Kong Monetary Authority.</p> <p>This report is disseminated in the United Kingdom by DBS Bank Ltd, London Branch ("DBS UK"). DBS UK is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request.</p> <p>In respect of the United Kingdom, this report is solely intended for the clients of DBS UK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS UK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.</p>
Dubai International Financial Centre	<p>This communication is provided to you as a Professional Client or Market Counterparty as defined in the DFSA Rulebook Conduct of Business Module (the "COB Module"), and should not be relied upon or acted on by any person which does not meet the criteria to be classified as a Professional Client or Market Counterparty under the DFSA rules.</p> <p>This communication is from the branch of DBS Bank Ltd operating in the Dubai International Financial Centre (the "DIFC") under the trading name "DBS Bank Ltd. (DIFC Branch)" ("DBS DIFC"), registered with the DIFC Registrar of Companies under number 156 and having its registered office at units 608 - 610, 6th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates.</p> <p>DBS DIFC is regulated by the Dubai Financial Services Authority (the "DFSA") with a DFSA reference number F000164. For more information on DBS DIFC and its affiliates, please see http://www.dbs.com/ae/our-network/default.page.</p> <p>Where this communication contains a research report, this research report is prepared by the entity referred to therein, which may be DBS Bank Ltd or a third party, and is provided to you by DBS DIFC. The research report has not been reviewed or authorised by the DFSA. Such research report is distributed on the express understanding that, whilst the information contained within is believed to be reliable, the information has not been independently verified by DBS DIFC.</p> <p>Unless otherwise indicated, this communication does not constitute an "Offer of Securities to the Public" as defined under Article 12 of the Markets Law (DIFC Law No.1 of 2012) or an "Offer of a Unit of a Fund" as defined under Article 19(2) of the Collective Investment Law (DIFC Law No.2 of 2010).</p> <p>The DFSA has no responsibility for reviewing or verifying this communication or any associated documents in connection with this investment and it is not subject to any form of regulation or approval by the DFSA. Accordingly, the DFSA has not approved this communication or any other associated documents in connection with this investment nor taken any steps to verify the information set out in this communication or any associated documents, and has no responsibility for them. The DFSA has not assessed the suitability of any investments to which the communication relates and, in respect of any Islamic investments (or other investments identified to be Shari'a compliant), neither we nor the DFSA has determined whether they are Shari'a compliant in any way.</p> <p>Any investments which this communication relates to may be illiquid and/or subject to restrictions on their resale. Prospective purchasers should conduct their own due diligence on any investments. If you do not understand the contents of this document you should consult an authorised financial adviser.</p>
United States	<p>This report was prepared by DBS Bank Ltd, DBS Bank (Hong Kong) Limited ("DBS HK"). DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.</p>
Other jurisdictions	<p>In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.</p>

Disclaimer: The information contained in this document is intended only for use by the person to whom it has been delivered and should not be disseminated or distributed to third parties without our prior written consent. DBS accepts no liability whatsoever with respect to the use of this document or its contents. Please refer to Disclaimer found at the end of this document

DBS Regional Research Offices

HONG KONG

DBS Bank (Hong Kong) Ltd

Contact: Dennis Lam
13th Floor One Island East,
18 Westlands Road,
Quarry Bay, Hong Kong
Tel: 852 3668 4181
Fax: 852 2521 1812
e-mail: dbsvhk@dbs.com

SINGAPORE

DBS Bank Ltd

Contact: Andy Lee Khoon SIM
12 Marina Boulevard,
Marina Bay Financial Centre Tower 3
Singapore 018982
Tel: 65 6878 8888
e-mail: groupresearch@dbs.com
Company Regn. No. 196800306E

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: William Simadiputra
DBS Bank Tower
Ciputra World 1, 32/F
Jl. Prof. Dr. Satrio Kav. 3-5
Jakarta 12940, Indonesia
Tel: 62 21 3003 4900
Fax: 6221 3003 4943
e-mail: indonesiaresearch@dbs.com

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul
989 Siam Piwat Tower Building,
14th-15th Floor
Rama 1 Road, Pathumwan,
Bangkok Thailand 10330
Tel. 66 2 857 7831
Fax: 66 2 658 1269
e-mail: DBSVTresearch@dbs.com
Company Regn. No 0105539127012
Securities and Exchange Commission, Thailand